Namyslowski G, Klimala J, Kokocinska D, Misiolek M
II ENT Department, Silesian Medical School, Zabrze, Poland.
Eur Arch Otorhinolaryngol. 1997;254 Suppl 1:S154-6. doi: 10.1007/BF02439749.
An attempt was undertaken to evaluate the usefulness of squamous cell carcinoma antigen (SCC Ag) in different stages of squamous cell carcinoma of the larynx. Antigen levels were determined in blood serum before treatment in 25 patients with laryngeal cancer treated at the II ENT Department, Silesian Medical School in Zabrze. Ages were 39-65 years (mean, 56.6 years). Fifteen healthy volunteers of similar ages served as controls. SCC Ag was estimated by an enzyme-immunological method using the Abbot set. Increasing levels of SCC Ag were found in 14 patients (65%). The mean SCC Ag level before treatment in the tumor group was 2.93 +/- 0.23 ng/ml and 0.79 +/- 0.19 ng/ml in the control group (standard, 1.5 ng/ml). Mean SCC Ag levels depending on the clinical stage of disease were: stage I, 1.52 ng/ml; stage II, 2.16 ng/ml; stage III, 3.03 ng/ml; stage IV, 4.57 ng/ml. Differences in all groups were statistically significant when compared to the healthy controls (P < 0.05).
开展了一项研究，以评估鳞状细胞癌抗原（SCC Ag）在喉鳞状细胞癌不同阶段的作用。对在扎布热西里西亚医学院第二耳鼻喉科接受治疗的25例喉癌患者治疗前血清中的抗原水平进行了测定。患者年龄为39 - 65岁（平均56.6岁）。15名年龄相仿的健康志愿者作为对照。采用雅培试剂盒通过酶免疫法对SCC Ag进行评估。14例患者（65%）的SCC Ag水平升高。肿瘤组治疗前SCC Ag平均水平为2.93±0.23 ng/ml，对照组为0.79±0.19 ng/ml（标准值为1.5 ng/ml）。根据疾病临床分期的SCC Ag平均水平分别为：I期，1.52 ng/ml；II期，2.16 ng/ml；III期，3.03 ng/ml；IV期，4.57 ng/ml。与健康对照组相比，所有组的差异均具有统计学意义（P < 0.05）。
